The possibilities for personalised vaccines in all types of cancer are revealed today in a lecture from Dr Harpreet Singh at the ESMO Symposium on Immuno-Oncology 2014 in Geneva, Switzerland.
“One of the biggest hurdles in cancer immunotherapy is the discovery of appropriate cancer targets that can be recognised by T-cells,” said Singh, who is scientific coordinator of the EU-funded GAPVAC phase I trial which is testing personalised vaccines in glioblastoma, the most common and aggressive brain cancer. “In the GAPVAC trial we will treat glioblastoma patients with vaccines that are ideal for each patient because they contain personalised antigens.”1
For all patients in the GAPVAC study, researchers will identify genes expressed in the tumour, peptides presented on the human leukocyte antigen (HLA) receptor (i.e. peptides which will be seen by T-cells), cancer specific mutations, and the ability of the immune system to mount a response to certain antigens. Based on this information, two vaccines, called actively personalised vaccines (APVACs), will be constructed and administered following conventional surgery.
The first vaccine will be prepared from a warehouse of 72 targets previously identified by the researchers as relevant for treatment in glioblastoma. These peptides have been manufactured and put on the shelf ready to be vaccinated in patients. Patients will be given a cocktail of the peptides they express and which their immune system can mount a response to.
Singh said: “A patient may express 20 of these 72 targets on their tumour, for example. If we find that the patient’s immune system can mount responses to 5 of the 20 targets, we mix the 5 peptides and give them to the patient. We mix the peptides off the shelf but the cocktail is changed for each patient because it is matched to their biomarkers.”
The second vaccine is synthesised de novo based on a mutated peptide expressed in the tumour of the patient. Singh said: “That peptide is not in our warehouse because it just occurs in this one single patient. The patient receives APVAC-1 and APVAC-2 in a highly personalised fashion in a way that I think has never been done for any patient.”
He added: “GAPVAC has two major goals. One is to show that personalised vaccines are feasible, since this is one of the most complicated trials ever done in cancer immunotherapy. The second is to show that we can mount far better biological responses in these patients compared to vaccination with non-personalised antigens.”
Singh’s previous research has shown that vaccination with non-personalised antigens leads to better disease control and longer overall survival in phase I and phase II clinical studies in patients with renal cell cancer.2
Singh said: “For the non-personalised vaccines we used off-the-shelf peptide targets that were shared by many patients with a particular cancer. Using this approach we have successfully vaccinated patients with renal cell cancer, colorectal cancer and glioblastoma.”
He added: “During this research we identified other targets that appeared in very few patients or even, in extreme cases, in a single patient. Often these rarer peptides are of better quality, meaning they are more specifically seen in cancer cells and occur at higher levels. This led us to start developing personalised cancer vaccines which contain the ideal set of targets for one particular patient. We hope they will be even more effective than the off-the-shelf vaccines.”
The Latest on: Personalised Vaccines
via Google News
The Latest on: Personalised Vaccines
- Scientific & Commercial Aspects of Personalized Medicine Markets, 2018-2019 & 2028on December 9, 2019 at 2:53 pm
Biological therapies such as those which use patient's own cells are considered to be personalized medicines. Vaccines are prepared from individual patient's tumor cells. Individualized therapeutic ...
- Sanofi To Raise Pandemic Influenza Vaccine Production Supported By Federal Fundson December 9, 2019 at 4:45 am
This investigational pandemic vaccine will utilize the same recombinant technology as Sanofi's influenza vaccine, Flublok Quadrivalent. SHARE THIS POST Sanofi NewsMORE your MARKET VIEW Your ...
- Nouscom - First Patient Dosed in a Phase 1 Trial With NOUS-209, an 'off-the-shelf' Neoantigen Cancer Vaccine, in MSI-High Solid Tumorson December 8, 2019 at 10:00 pm
BASEL, Switzerland, Dec. 9, 2019 /PRNewswire/ -- Nouscom, an immuno-oncology company developing off-the-shelf and personalized cancer neoantigen vaccines, announced today that the first patient has ...
- GeoVax to Present at World Vaccine & Immunotherapy Conferenceon December 3, 2019 at 5:00 am
GeoVax’s HIV vaccine is also part of collaborative efforts to develop an immunotherapy as a functional cure for HIV. For more information, visit www.geovax.com. Markets Insider and Business Insider ...
- Trials of pancreatic cancer vaccine show promiseon November 29, 2019 at 10:14 am
Another important aspect of the vaccine is that it has the potential to be personalized. The genetic makeup of cancer varies from patient to patient, so a treatment that is effective in one person ...
- New finding may lead to a vaccine for pancreatic canceron November 29, 2019 at 3:08 am
In a new study, researchers have developed a personalized vaccine system that could ultimately delay pancreatic cancer. The study provides a strong proof-of-concept for the creation of a vaccine for ...
- Researchers develop vaccine with potential to treat pancreatic canceron November 27, 2019 at 10:34 am
A study has demonstrated that a novel vaccine design for pancreatic cancer has been successful in mice, doubling survival time. A personalised vaccine system to delay the onset of pancreatic cancer ...
- Engineering dendritic cell vaccines to improve cancer immunotherapyon November 27, 2019 at 2:23 am
Integrating new knowledge of DC biology and advancements in cell engineering, we provide a blueprint for the rational design of optimized DC vaccines for personalized cancer medicine. DCs consist of ...
- UK and China research team take first steps towards a vaccine for pancreatic canceron November 26, 2019 at 1:12 pm
Researchers from Queen Mary University of London and Zhengzhou University have developed a personalised vaccine system that could ultimately delay the onset of pancreatic cancer. The study provides ...
- Newly developed personalized vaccine system could delay onset of pancreatic canceron November 26, 2019 at 10:44 am
Researchers from Queen Mary University of London and Zhengzhou University have developed a personalized vaccine system that could ultimately delay the onset of pancreatic cancer. The study provides ...
via Bing News